1. Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

2. Proportional effects on cause-specific mortality per mmol/L LDL cholesterol reduction Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

3. Proportional effects on major vascular events per mmol/L LDL cholesterol reduction Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

4. Relation between proportional reduction in incidence of major coronary events and major vascular events and mean absolute LDL cholesterol reduction at 1 year Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

5. Proportional effects on major vascular events per mmol/L LDL cholesterol reduction by year Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

6. Proportional effects on major coronary events per mmol/L LDL cholesterol reduction subdivided by baseline prognostic factors Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

7. 5-year absolute benefits on particular vascular outcomes per mmol/L LDL cholesterol reduction in participants with and without previous MI or CHD Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

8. Proportional effects on major vascular events per mmol/L LDL cholesterol reduction subdivided by baseline prognostic factors Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

9. Proportional effects on cancer incidence per mmol/L LDL cholesterol reduction by site Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

10. Proportional effects on cancer incidence per mmol/L LDL cholesterol reduction by year Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78